Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Verve Therapeutics

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
From Verve Therapeutics
Via Globe NewsWire
Tickers VERV
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Verve Therapeutics
Via Globe NewsWire
Tickers VERV
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via Globe NewsWire
Tickers VERV
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via Globe NewsWire
Tickers VERV
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via Globe NewsWire
Tickers VERV
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
From Verve Therapeutics
Via Globe NewsWire
Tickers VERV
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
From Verve Therapeutics
Via Globe NewsWire
Tickers VERV
Verve Therapeutics Announces Pricing of Initial Public Offering
From Verve Therapeutics
Via Business Wire
Tickers VERV
Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors
From Verve Therapeutics
Via Business Wire
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
From Verve Therapeutics
Via Business Wire
Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT
From Verve Therapeutics
Via Business Wire
Verve Therapeutics Appoints Industry Leader Sheila Mikhail to its Board of Directors
From Verve Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.